Australia-based Propanc Biopharma announced it secured up to $100 million in funding from Hexstone Capital to build a crypto treasury and accelerate development of its lead cancer therapy PRP, which targets metastatic solid tumors. The private placement, structured as convertible preferred stock, includes an initial $1 million with up to $99 million available over the next 12 months.